



ELSEVIER

Contents lists available at [ScienceDirect](#)

Lung Cancer

journal homepage: www.elsevier.com/locate/lungcan



Erratum

Erratum to “Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib” [Lung Cancer, 108 (June 2017) 228–231]



Sai-Hong Ignatius Ou^{a,*}, Jean Cui^b, Alexa B. Schrock^c, Michael E. Goldberg^c, Viola W. Zhu^{a,d}, Lee Albacker^c, Philip J. Stephens^c, Vincent A. Miller^c, Siraj M. Ali^c

^a Chao Family Comprehensive Cancer Center, University of California, Irvine School of Medicine, Orange, CA, USA

^b TP Therapeutics Inc, San Diego, CA, USA

^c Foundation Medicine Inc, Cambridge, MA, USA

^d Veterans Affairs Long Beach Healthcare System, Long Beach, CA, USA

The publisher regrets the title was published with an error. This has now been corrected.

The publisher would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.lungcan.2017.04.003>

* Corresponding author at: Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California, Irvine School of Medicine, 101 City Drive, Bldg 56, RT81, Rm 241 Orange, CA, 92868, USA.

E-mail address: ignatius.ou@uci.edu (S.-H.I. Ou).

<https://doi.org/10.1016/j.lungcan.2019.08.013>